<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622372</url>
  </required_header>
  <id_info>
    <org_study_id>TRFDP1</org_study_id>
    <nct_id>NCT03622372</nct_id>
  </id_info>
  <brief_title>Zone 2 Flexor Tendon Repair With CoNextions TR Implant System</brief_title>
  <official_title>Pivotal, Randomised, Controlled Trial to Evaluate the Safety and Effectiveness of the CoNextions TR Implant System for Zone 2 Flexor Tendon Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CoNextions Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CoNextions Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomised, controlled trial of a novel implant intended for use during surgical
      repair of lacerated Zone 2 flexor digitorum profundus tendons.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned using a 1:1 randomization scheme to receive either the investigational device or a suture repair for the surgical treatment of their tendon lacerations.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants and the Occupational Therapist performing the majority of the outcome assessments will be masked to the treatment until the 12 week post-operative visit.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of tendon re-rupture</measure>
    <time_frame>24 weeks</time_frame>
    <description>Primary Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mobility of the affected digits using Strickland's Revised Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Primary Effectiveness Endpoint-Strickland's Revised Score provides a descriptive measure of the mobility of digits. Range of motion measurements taken on the studied digits are used to generate a score on a 0 (least mobile) to 100 (most mobile) with outcomes being classified as: excellent (75-100%), good (50-784%), fair (25-49%), or poor (&lt;25%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score (VAS) for Pain Assessment (0-10 cm scale)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patient reported pain intensity measuring from 0 (no pain) to 10 (worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Site Infection</measure>
    <time_frame>24 weeks</time_frame>
    <description>Presence of infection at the surgical site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH) Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>DASH is a patient-reported questionnaire consisting of 30 questions designed to evaluate a patients ability to perform certain upper extremity activities. The patients answers are used to calculate a score from 1 (most disabled) to 100 (least disabled). DASH is validated to be able to detect small and large changes over time, most notably before and after surgical interventions in the upper extremity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength measured using a dynamometer with values for the affected hand being calculated as a percentage of the grip strength of the unaffected hand</measure>
    <time_frame>24 weeks</time_frame>
    <description>The average of three grip strength values taken in succession (kilograms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tip pinch strength measured with a pinch gauge with values for the affected fingers calculated as a percentage of the tip pinch strength for corresponding fingers on the unaffected hand</measure>
    <time_frame>24 weeks</time_frame>
    <description>The average of three tip pinch strength values taken in succession (kilograms).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Tendon Injury - Hand</condition>
  <arm_group>
    <arm_group_label>CoNextions TR Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suture Repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Operative repair of Zone 2 FDP tendon lacerations</intervention_name>
    <description>Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator</description>
    <arm_group_label>CoNextions TR Implant</arm_group_label>
    <arm_group_label>Suture Repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoNextions TR Implant System</intervention_name>
    <description>The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).</description>
    <arm_group_label>CoNextions TR Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>4-strand locked cruciate repair</intervention_name>
    <description>A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).</description>
    <arm_group_label>Suture Repair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Willing and able to provide a signed and dated informed consent form

          3. Stated willingness to comply with all study procedures

          4. Available for the duration of the study

          5. Have one or two fully lacerated digital FDP tendon(s), with or without a concomitant
             injury of the flexor digitorum superficialis, in Zone 2 of the index, middle, ring, or
             small finger

          6. Tendon laceration occurred within the previous 14 days

        Exclusion Criteria:

          1. Pregnant or planning to become pregnant during the follow-up period

          2. Autoimmune disorder(s)

          3. Type 1 diabetes mellitus or clinical history of poorly controlled Type 2 diabetes
             mellitus

          4. Lack of proper cutaneous coverage at repair site

          5. Concomitant fracture

          6. Amputated digit(s)

          7. Arthritis of the hand

          8. Prior hand trauma with residual impact to function

          9. Congenital hand defect

         10. Conditions that would affect comparative measurements in the uninjured hand

         11. Tendon laceration caused by a crush injury

         12. Prior sensory impairment in digits of either hand. Note: Participants with nerve
             injuries associated with the trauma causing the current flexor tendon injury are
             eligible for enrollment

         13. Vascular injuries that require revascularisation procedures

         14. Ischemia and/or blood supply compromise

         15. Prior or current infections at or near the intended implant site

         16. Active sepsis, MRSA, or other conditions that may prevent healing

         17. History of foreign-body sensitivity to 316 L Stainless Steel or UHMWPE

         18. Implantation of CoNextionsTR Implant would result in physical contact with other metal
             implants made of material other than implant grade stainless steel such as titanium,
             titanium alloys, cobalt chromium, or other dissimilar metals

         19. Any condition(s) which, in the opinion of the investigator, may impact the
             participant's ability to properly follow-up or otherwise be at-risk for following
             protocol instructions

         20. Currently participating in another clinical/device trial

             The following criteria, determined during the surgical procedure, will also cause an
             individual to be excluded from the study:

         21. Surgical site access less than 20 mm in total or less than 10 mm on either side of
             intended implant site

         22. Injured tendon is outside of the width range (3.0-7.0 mm) and thickness range (1.5-4.0
             mm) specified for the CoNextionsTR Implant System.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Solomons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grootte Schuur Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Swift</last_name>
    <phone>2014190118</phone>
    <email>mswift@conextionsmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Attila Poka, MD</last_name>
    <phone>6142845497</phone>
    <email>apoka@conextionsmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grootte Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelebogile Seloka</last_name>
      <phone>27216501447</phone>
      <email>lebo.seloka@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Michael Solomons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duncan McGuire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Abrahams</last_name>
      <phone>27825166586</phone>
      <email>tyer@sun.ac.za</email>
    </contact>
    <investigator>
      <last_name>Ajmal Ikram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inkosi Albert Luthuli Central Hosptial</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leorna Sewnarain</last_name>
      <phone>27739634573</phone>
      <email>lee.sewnarain@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antoine Rocher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hosptial</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Grisillo-Biscardi</last_name>
      <phone>27713960262</phone>
      <email>anna.grisillo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>LG Biddulph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FLEXOR TENDON</keyword>
  <keyword>ZONE 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendon Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

